Moreover, in TP53-mutant r/r DLBCL PDCs, pre-treatment with the USP7 inhibitor significantly boosted the subsequent cytotoxicity of CD19 CAR-T cells. This evidence concerns the gene USP7 and diffuse large B-cell lymphoma.